Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CAR-T update

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Oct 06, 2023 1:58am

128 Views

Post# 35672544

RE:RE:RE:RE:RE:RE:RE:CAR-T update

They are tolerated, they're just argued with. Same way you argue with positive, informative posts.

Your only argument is that it hasn't happened yet or before. There's lots going on that hasn't happened yet or before.

Share price stinks and no one is happy about it. Doesn't change the data and information about Pela's standing and potential.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing